GET DAILY SIGNALSWhy Is Lumexa Imaging Holdings (LMRI) Stock Up +13.58% Today?
Key Takeaways
- LMRI shares surged 13.58% to $15.81, up $1.89 from the prior session's close of $13.92.
- The primary catalyst was a stronger-than-expected third-quarter earnings report and a raised full-year profit outlook.
- Adjusted EPS of $0.26 beat consensus near $0.18–$0.20, while revenue of $271.97 million edged past estimates of roughly $269.9 million.
- Secondary drivers included record advanced-modality mix, robust free cash flow, and a CMS site-neutral payment rule that expands the company's addressable market.
- Broader healthcare and small-cap sentiment reinforced the earnings-driven move.
- Traders are now watching fourth-quarter volume ramp and full-year cash conversion for confirmation.
- For deeper insight, review Price Targets, Earnings, and Forecast data on Tickeron.
- Explore Trending AI Robots to see how automated strategies are positioning across the market.
Opening Summary
Lumexa Imaging Holdings, Inc. (LMRI), a national provider of diagnostic imaging services spanning MRI, CT, PET, X-ray, ultrasound, and mammography, rallied sharply on Wednesday. The stock climbed 13.58% to $15.81, up from a prior close of $13.92, as investors digested a third-quarter earnings report that outpaced expectations and brought a higher full-year profit forecast. Markets attributed the move primarily to the company's earnings beat, improving profitability mix, and management's raised adjusted EPS guidance, reinforced by a favorable regulatory backdrop for outpatient imaging.
Earnings Results and Raised Guidance
The earnings-driven move followed Lumexa's third-quarter release, in which adjusted earnings per share of $0.26 cleared consensus estimates of roughly $0.18 to $0.20. Revenue of $271.97 million increased about 5% year over year and edged past the approximately $269.9 million consensus. Most notably, management raised its full-year 2026 adjusted EPS outlook to a range of $0.86 to $0.90, up from a prior range of $0.71 to $0.77, signaling confidence in sustained profitability through year-end.
The results also marked a GAAP swing to net income of $7.2 million from a loss a year earlier, while adjusted EBITDA rose 11% sequentially. Free cash flow of $20.6 million represented roughly a 32.9% conversion of adjusted EBITDA, and management lifted its full-year cash conversion guidance to at least 30%. This improving cash-generation profile reinforced the bullish reaction among investors.
Advanced Modalities, Joint Ventures, and Site-Neutral Tailwind
Beyond the headline numbers, several operational catalysts supported the price rally. Advanced modalities, which reimburse at three to four times routine scans, reached a record 38.2% of system-wide volume, up 145 basis points year over year. The company also expanded its joint venture with Advocate Health into Illinois, its tenth health-system partnership, and opened three new de novo centers in early November.
A favorable regulatory development added further support. The Centers for Medicare & Medicaid Services finalized a 2027 hospital outpatient site-neutral payment rule that reduces reimbursement advantages for hospital outpatient departments. Management framed this as meaningfully expanding Lumexa's total addressable market to roughly $77 billion, strengthening the long-term rationale for lower-cost freestanding imaging.
Market Context and Trading Activity
The move came on the first full trading session following the earnings release, with active participation reflecting renewed institutional interest in the name. Lumexa's rally outpaced the broader healthcare sector and reflected a rotation into a growth story supported by durable outpatient imaging demand, an aging population, and increasing use of advanced imaging. The stock has now extended gains from earlier November strength, and the advance carried shares well above prior resistance levels, reinforcing bullish technical momentum. Analysts covering the company maintain a consensus Buy rating, with an average price target above recent trading levels.
What Comes Next for LMRI
Investors will now watch whether Lumexa can sustain its fourth-quarter momentum, including the ramp of newly opened de novo centers and continued advanced-modality mix improvement. Management has signaled that formal 2027 guidance will arrive in March, while preliminary analysis suggests Medicare reimbursement could come in modestly below prior assumptions, though commercial contracts are largely settled. Risks include higher capital expenditures, litigation-related costs, and the possibility that the raised EPS outlook was driven partly by a lower assumed tax rate rather than purely operational improvement. The company's ability to convert top-line growth into durable free cash flow remains the central focus for the quarters ahead.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each designed around distinct strategies, timeframes, and performance metrics. Only the strongest performers under current market conditions are featured in the curated Trending AI Robots section, helping traders identify automated approaches that are outperforming right now. Explore the page to see which strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LMRI in upward trend: price rose above 50-day moving average on October 23, 2026
LMRI moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend. In 4 of 4 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on LMRI as a result. In 11 of 13 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for LMRI just turned positive on October 06, 2026. Looking at past instances where LMRI's MACD turned positive, the stock continued to rise in 4 of 5 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for LMRI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 1 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +5.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMRI advanced for three days, in 38 of 46 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 15 of 19 cases where LMRI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMRI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
LMRI broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.098) is normal, around the industry mean (4.142). P/E Ratio (-46.532) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.075) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LMRI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LMRI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement